Faricimab for Chronic Central Serous Chorioretinopathy
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests whether faricimab (a medicine injected into the eye) can help reduce fluid buildup in patients with chronic central serous chorioretinopathy (CSCR). It compares the drug to a sham injection to see if it improves vision and reduces fluid.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 21 years or older.
- You have chronic central serous chorioretinopathy (CSCR) with fluid that has been present for at least 3 months.
- The fluid involves the center of your vision (fovea) and your choroid (the layer under the retina) is thicker than normal.
- Your vision in the study eye is between 20/32 and 20/300 (moderate to severe vision loss).
- You have not had prior treatments like anti-VEGF injections in the last 6 months, photodynamic therapy ever, or steroid injections in the study eye.
- You are not pregnant or breastfeeding, and if you can become pregnant, you agree to use reliable birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special eye scan to look at the back of the eye in people with central serous chorioretinopathy (CSC). It aims to better understand the condition and may help guide future treatments.
This study looks at the link between gut bacteria and central serous chorioretinopathy (CSC), a condition where fluid builds up under the retina. It may help us understand why some people get CSC and find better ways to treat it.
This study measures blood flow in the eye in people with acute or chronic central serous chorioretinopathy (CSC). It uses eye scans and special imaging to better understand what’s happening and whether it may differ between short-term and long-term disease.
This study tests a personalized treatment plan using an investigational drug called faricimab for people who have a specific type of wet age-related macular degeneration known as polypoidal choroidal vasculopathy. The goal is to see if adjusting the time between injections based on your individual needs can safely dry up fluid in the retina and improve vision.
This trial tests a drug called faricimab (brand name Vabysmo) for treating abnormal blood vessel growth in the back of the eye, caused by a past infection with histoplasmosis. The goal is to see if it helps improve vision over 52 weeks.
This trial tests a low-energy “subthreshold” laser to treat long-lasting fluid under the retina from central serous chorioretinopathy (CSCR). It may help dry up the fluid and improve vision, compared with a sham (placebo) treatment.
Hear when a new Central Serous Chorioretinopathy (CSC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.